Sep 2, 2026 08:00AM
Aug 19, 2026 04:05PM
Aug 6, 2026 08:00AM
Jul 28, 2026 04:05PM
Jul 2, 2026 04:05PM
Jun 30, 2026 07:56AM
Jun 2, 2026 04:05PM vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026 04:01PM
May 8, 2026 04:15PM
May 7, 2026 08:00AM
Apr 7, 2026 04:15PM
Mar 16, 2026 08:00AM
Mar 12, 2026 06:43AM
Mar 10, 2026 04:01PM vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 13, 2026 08:00AM
Feb 2, 2026 08:01AM
Feb 2, 2026 08:00AM
Dec 18, 2025 04:05PM
Dec 18, 2025 04:05PM
Nov 6, 2025 04:15PM
Oct 9, 2025 08:00AM vTv Therapeutics adds four experts to scientific advisory board
Oct 9, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 11, 2025 08:00AM
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
May 15, 2025 12:00PM vTv Therapeutics (VTVT) Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
May 15, 2025 12:00PM
Apr 9, 2025 06:03AM
Mar 20, 2025 05:35PM
Mar 17, 2025 08:30AM
Mar 17, 2025 08:30AM
Dec 9, 2024 07:33AM
Nov 12, 2024 04:05PM vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
Aug 8, 2024 04:15PM
Jul 26, 2024 04:05PM
Jul 26, 2024 04:05PM
Jun 24, 2024 04:08PM
Jun 24, 2024 04:05PM
May 28, 2024 08:00AM
May 20, 2024 12:00PM CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
May 9, 2024 04:51PM
Mar 19, 2024 08:30AM
Mar 13, 2024 08:00AM
Mar 4, 2024 08:00AM
Mar 4, 2024 08:00AM
Nov 2, 2023 08:05AM
Nov 2, 2023 08:00AM vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Aug 11, 2023 04:31PM

330,680 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All